Wall Street Zen Upgrades MediWound (NASDAQ:MDWD) to “Sell”

MediWound (NASDAQ:MDWD) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.

Several other brokerages have also commented on MDWD. Weiss Ratings lowered MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. Oppenheimer reissued an “outperform” rating and set a $30.00 price target (down from $32.00) on shares of MediWound in a report on Friday, August 14th. Alliance Global Partners restated a “buy” rating on shares of MediWound in a research note on Wednesday, September 16th. Finally, TD Cowen reaffirmed a “buy” rating on shares of MediWound in a report on Thursday. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.00.

MediWound Price Performance

Shares of MediWound stock opened at $13.84 on Friday. The business’s 50 day simple moving average is $13.66 and its two-hundred day simple moving average is $15.05. The stock has a market capitalization of $177.84 million, a P/E ratio of -7.69 and a beta of 0.14. MediWound has a one year low of $12.52 and a one year high of $20.03.

MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01). The business had revenue of $3.09 million for the quarter, compared to the consensus estimate of $2.59 million. MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. Sell-side analysts expect that MediWound will post -2.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In other MediWound news, COO Shmuel Hess sold 3,958 shares of the stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $12.92, for a total transaction of $51,137.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in MediWound stock. Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of MediWound Ltd. (NASDAQ:MDWD) by 22.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 71,000 shares of the biopharmaceutical company’s stock after acquiring an additional 13,196 shares during the quarter. Clal Insurance Enterprises Holdings Ltd owned 0.55% of MediWound worth $1,311,000 as of its most recent SEC filing. Institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative enzymatic therapies for tissue injury and wound care. The company’s products are designed to remove damaged or nonviable tissue while helping preserve healthy tissue, supporting wound management and healing.

MediWound’s lead commercial product is NexoBrid, a topical bromelain-based therapy used for the enzymatic removal of eschar in adults with deep partial-thickness and full-thickness thermal burns.